Pharmadule Morimatsu AB Revenue and Competitors
Estimated Revenue & Valuation
- Pharmadule Morimatsu AB's estimated annual revenue is currently $14.9M per year.
- Pharmadule Morimatsu AB's estimated revenue per employee is $201,000
- Pharmadule Morimatsu AB has 74 Employees.
- Pharmadule Morimatsu AB grew their employee count by 9% last year.
Pharmadule Morimatsu AB Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Pharmadule Morimatsu AB?
Pharmadule designs, fabricates and delivers Turnkey production facilities for the Life Science and Consumer Goods Industries from Conceptual design to IQ/OQ complete. Since 1986, more than 70 production facilities have been successfully delivered. Our predictable and well-proven delivery model will ensure the success of your project - meeting the market demand and maximizing your return on investment. We use an off-site modular concept which makes us certain to consistently deliver high quality facilities regardless of final location.That's the Power of Certainty - to deliver Fast, on Schedule and on Budget. Leading pharmaceutical companies such as Eli Lilly, Merck, Baxter, GlaxoSmithKline, Genentech, Pharmacia and AstraZeneca have all used the modular approach for their new manufacturing buildings worldwide. Since 2011, Pharmadule is owned by Morimatsu Group Japan forming Pharmadule Morimatsu AB with head office in Stockholm Sweden. Pharmadule Morimatsu is continuing the success Pharmadule AB has had as the world leader in modular facilities. Since 1986, more than 60 production facilities have been successfully delivered to the pharmaceutical and biopharmaceutical industries worldwide utilizing Pharmadule's unique modular concept.keywords:N/A
Number of Employees
Employee Growth %
Pharmadule Morimatsu AB News
STOCKHOLM--(BUSINESS WIRE)--Morimatsu Industry Co., Ltd., the privately owned Japanese pioneer of tank technology, has acquired ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|